US Patent Litigations are now available. Check here

EP3506931

REGENERON PHARMACEUTICALS
Application Number
EP17771619A
Filing Date
Aug 31, 2017
Status
Granted And Under Opposition
Jun 27, 2024
Grant Date
Jul 31, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP3506931B1 was granted on Jul 31, 2024 by Regeneron Pharmaceuticals The patent is currently Granted And Under Opposition.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTApr 30, 2025ADMISSIBLE
HAMPTON KNOWLESApr 30, 2025ADMISSIBLE
SECERNAApr 30, 2025ADMISSIBLE
LUIGIApr 29, 2025ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionWO2014031610
N/A
OppositionWO2015127229
N/A
OppositionWO2016077675
N/A
OppositionWO2022076289
N/A
OppositionWO2018045130
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.